TECNOTREE
10.6.2022 13:47:07 CEST | Business Wire | Press release
Tecnotree, a Finland-based global provider of digital transformation solutions for Digital Service Providers (DSPs), today announced that it has been selected as ‘MongoDB Independent Software Vendor (ISV) Partner of the Year - Telco’ winner in the annual MongoDB World event at New York.
Padma Ravichander, CEO Tecnotree, said “We are proud to receive this award from MongoDB for helping our customers transition to new technologies and build digital ecosystems. Our technology platform allows customers to quickly deploy new services in response to market demand. Tecnotree’s digital BSS suite 5 provides end-to-end digital transformation for our enterprise customers, creating new efficiencies along the value chains. We are honoured to have this partnership with MongoDB. As we prepare for another exciting year ahead, we will continue to work closely with them to build custom-tailored solutions for our consumers.”
‘The MongoDB Partner of the Year Awards’ honour projects and people that thrive to help MongoDB telecom customers with their journey to the cloud. They celebrate the ground-breaking use of data to build compelling applications, modernize legacy ones, and the creativity of professionals expanding the limits of technology with MongoDB. This year partners were selected based on MongoDB end customer impact and influence.
Tecnotree was selected based on its unique set of offerings in the form of Cloud management, mobility and IoT, enterprise application development, software maintenance, and real-time offerings for enhanced customer experience, with their complete range of BSS Suite products and services. Tecnotree is addressing its goals towards building digital ecosystems by providing enterprises with a variety of solutions that help them with their digital transformation journey, using MongoDB as the underlying technology.
“At MongoDB, our partners are critical to our ability to care for our customers. The last two years have been a remarkably challenging time, with widespread changes affecting the entire world—and certainly the IT industry—like never before. However, this time has also brought customers and partners together to solve common problems,” said Alan Chhabra, Executive Vice President of Worldwide Partners, MongoDB. “At MongoDB, we’re committed to helping our customers evolve to this next stage of necessary innovation and are so grateful to all our partners who help make it happen. We’re cheering on this year's winners to carry on this competition’s legacy of honouring game-changing ideas, and I look forward to seeing the influence they make on the industry and the future.”
About Tecnotree
Tecnotree is the full-stack digital business management solution provider for digital service providers, with over 40 years of deep domain knowledge, proven delivery, and transformation capability across the globe. Our open-source technology-based agile products comprise the full range (order-to-cash) of business process and subscription management for telecom and DSPs with a pre-integrated B2B2X partner ecosystem across gaming, health, education, OTT, etc. Tecnotree products, platforms, and partners support emerging ecosystems of over 1 Billion subscribers across 70+ countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom